1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Inovio surprised by Roche returning prostate cancer immunotherapy

 
• By Eleanor Malone

The CEO of Inovio Pharmaceuticals has said the decision of its partner Roche to return rights to its prostate cancer immunotherapy "was a surprise to us". Dr Joseph Kim, Inovio's president and CEO, told Scrip that the company had no idea the collaboration was about to be terminated when Inovio reported Q3 results on 10 November and said it was expecting to begin Phase I trials of the preclinical DNA vaccine with Roche in 2015. "We were told on Friday [14 November] and announced it first thing Monday [17 November]," he said. "I believe it was a surprise to the Roche development team as well," he added.

The CEO of Inovio Pharmaceuticals has said the decision of its partner Roche to return rights to its prostate cancer immunotherapy "was a surprise to us". Dr Joseph Kim, Inovio's president and CEO, told Scrip that the company had no idea the collaboration was about to be terminated when Inovio reported Q3 results on 10 November and said it was expecting to begin Phase I trials of the preclinical DNA vaccine with Roche in 2015. "We were told on Friday [14 November] and announced it first thing Monday [17 November]," he said. "I believe it was a surprise to the Roche development team as well," he added.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.